Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on LinkedIn:
“In an interview with Cancer Network, Vice of USMIRC Shebli Atrash, MD, MS, FACP discussed his presentation on T-cell engagers in multiple myeloma that he gave at the 2025 National Immune Cell Effector Therapy ICE_T Conference.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.”
More posts featuring Al-Ola A Abdallah.